01—Abstract
Summary
Summary of the 8-K filed May 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Viatris Inc. (Nasdaq: VTRS) filed this Current Report on Form 8-K dated May 5, 2025 to disclose Board changes.
The Board increased its size from 12 to 14 directors and appointed Frank D'Amelio and Michael Severino as independent directors, effective immediately, with terms expiring at the 2025 annual meeting of shareholders. Mr. D'Amelio joined the Finance Committee and Dr. Severino joined the Science and Technology Committee. Both will receive non-employee director compensation consistent with the company's other directors, and both have entered into indemnification agreements with the company.
In the same filing, directors Rajiv Malik and Harry Korman notified the company that they will not stand for re-election at the 2025 Annual Meeting and will retire from the Board at the end of their current terms. The filing states that neither retirement resulted from any disagreement with the company on its operations, policies, or practices. The company issued a press release on the same day, attached as Exhibit 99.1, describing the appointments and retirements; the Board chair and CEO commented on the transition in that release.
The filing is focused on governance and board refreshment rather than financial results. It contains no financial figures, and the press release frames the changes as part of the company's ongoing Board refreshment efforts.
02—Key points
Key Highlights
- Board size increased from 12 to 14 directors, with Frank D'Amelio and Michael Severino appointed as independent directors effective May 5, 2025.
- Mr. D'Amelio was appointed to the Finance Committee and Dr. Severino to the Science and Technology Committee.
- Directors Rajiv Malik and Harry Korman will retire at the end of their current terms, expiring at the 2025 Annual Meeting of Shareholders.
- The filing states the retirements were not the result of any disagreement with the company on its operations, policies, or practices.
- Both new directors will receive compensation consistent with the company's other non-employee directors and have entered into indemnification agreements with the company.
- Mr. D'Amelio brings a background as former Executive Vice President & CFO at Pfizer, with roughly 15 years as Pfizer CFO according to the press release.
- Dr. Severino currently serves as CEO of Tessera Therapeutics and CEO-Partner of Flagship Pioneering, and previously held senior roles at AbbVie and Amgen.
03—Questions
Frequently Asked Questions
Who are the new directors and when did they join the Board?
Frank D'Amelio and Michael Severino were appointed to Viatris' Board of Directors on May 5, 2025, effective immediately. Their terms expire at the company's 2025 annual meeting of shareholders.
Why are Rajiv Malik and Harry Korman leaving the Board?
Malik and Korman each notified the company that they will not stand for re-election at the 2025 Annual Meeting and will retire at the end of their current terms. The filing states that neither retirement resulted from a disagreement with the company on its operations, policies, or practices.
Do the new directors have any material interests or arrangements with the company?
The filing states that there are no arrangements or understandings between either new director and any other person under which they were selected as a director. It also states that neither has a direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
What committees will the new directors serve on?
Frank D'Amelio was appointed to the Finance Committee, and Dr. Michael Severino was appointed to the Science and Technology Committee, both effective May 5, 2025.
Does this filing include financial results or guidance?
No. The filing addresses Board appointments and retirements only. The attached press release (Exhibit 99.1) announces the Board changes and does not contain financial results or guidance.
04—Continue